Cetrorelix vs hCG

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval. Clinical studies including randomized controlled trials have established cetrorelix as an effective option for LH surge prevention in IVF and ICSI cycles, with well-characterized safety and efficacy data across multiple formulations. Cetrorelix is an FDA-approved prescription medication (Cetrotide) indicated for use under specialist supervision in fertility treatment settings. Cetrorelix dosing protocols and IVF context Per FDA labeling (Cetrotide), cetrorelix is available in two protocols for IVF: the multiple-dose protocol (0.25 mg subcutaneously once daily during ovarian stimulation) and the single-dose protocol (3 mg subcutaneously in a single injection). Specific timing, trigger criteria, and supplemental dosing schedules are determined by the treating reproductive endocrinologist per the full FDA prescribing information. Cetrorelix vs ganirelix: Cetrorelix (Cetrotide) and ganirelix (Antagon, Orgalutran) are both GnRH receptor antagonists used in the same IVF indication. Both act as competitive antagonists at the pituitary GnRH receptor, producing rapid suppression without the initial LH flare seen with agonists. They are pharmacologically equivalent in mechanism; differences relate to proprietary formulation, dosing schedule in specific protocols, and market availability in different regions. Neither requires the weeks-long downregulation period that GnRH agonist protocols (triptorelin, leuprolide) involve — antagonist protocols can begin mid-stimulation, reducing the total cycle length. Cetrorelix and ganirelix are both prescription-only fertility medications requiring specialist reproductive endocrinology supervision.

Glycoprotein hormone binding LH receptor on Leydig cells; stimulates testosterone production; prevents testicular atrophy during TRT; maintains spermatogenesis via FSH-like activity

Human chorionic gonadotropin (hCG) is a glycoprotein hormone that acts as a functional analogue of luteinizing hormone (LH), binding to LH receptors on Leydig cells in the testes and granulosa cells in the ovaries to stimulate steroidogenesis. In men, hCG stimulates testicular testosterone production directly, making it a widely used clinical tool for hypogonadotropic hypogonadism, male fertility support, and preservation of testicular function alongside testosterone replacement therapy. Clinical research demonstrates hCG effectiveness for improving testosterone levels and sperm parameters in males with gonadotropin deficiency, as well as for triggering final oocyte maturation in IVF protocols. hCG is an FDA-regulated biologic available in multiple approved formulations; use requires physician supervision due to dose-dependent effects on testosterone, estradiol, and reproductive signaling. hCG dosage in TRT support: in men using testosterone replacement therapy, hCG is prescribed to prevent testicular atrophy and maintain intratesticular testosterone levels needed for spermatogenesis. Typical clinical doses range from 250 to 500 IU subcutaneously administered 2–3 times per week, though protocols vary by provider and individual response. At higher doses, hCG's stimulation of testicular testosterone can also increase aromatization to estradiol — a clinically relevant consideration in TRT management requiring estrogen monitoring. hCG vs gonadorelin: both are used in men's health for testicular preservation alongside TRT, but they act at different axis levels. hCG acts directly on Leydig cell LH receptors, bypassing the pituitary entirely — a direct trophic signal to the testes. Gonadorelin acts upstream at the pituitary to stimulate endogenous LH and FSH release, preserving the full hypothalamic-pituitary-gonadal axis including FSH-driven spermatogenesis. For men prioritizing sperm production, gonadorelin's preservation of FSH signaling offers a potential advantage; for men primarily focused on testicular volume and intratesticular testosterone maintenance, hCG provides a well-validated, direct approach. Telehealth and men's health providers offering hCG and gonadorelin protocols are listed in the PeptideBase directory.